Skip to main content
F3 Platform Biologics, Inc. (JDRR)
F3 Platform Biologics was planning to go public, but the IPO was withdrawn on Jun 20, 2024.
Stock Price: Pending
IPO price not available yet

F3 Platform Biologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
 20222021
Selling, General & Admin
0.371.89
Research & Development
0.250.03
Operating Expenses
0.621.93
Operating Income
-0.62-1.93
Interest Expense / Income
0.30.28
Pretax Income
-0.93-2.21
Net Income
-0.93-2.21
Free Cash Flow
-0.39-0.1
EBITDA
-0.62-1.93
EBIT
-0.62-1.93
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).